Literature DB >> 17990907

Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.

Katarzyna Kotulska1, Magdalena Larysz-Brysz, Wieslława Grajkowska, Jarosław Jóźwiak, Paweł Włodarski, Mustafa Sahin, Joanna Lewin-Kowalik, Dorota Domańska-Pakieła, Sergiusz Jóźwiak.   

Abstract

Cardiac rhabdomyoma (CR) is the most common heart tumor in children and is usually associated with tuberous sclerosis complex (TSC). Tuberous sclerosis complex is a genetic disorder caused by a mutation in either of 2 genes (TSC1 or TSC2) and characterized by the formation of hamartomas in multiple organs. The 2 TSC proteins, hamartin and tuberin, antagonize the mammalian target of rapamycin (mTOR) signaling pathway, thus regulating cell growth and proliferation. Recently, some trials treating TSC with the mTOR inhibitor rapamycin have been published; however, the impact of such treatment on heart tumors is not known. The aim of the present paper was to study the molecular pathobiology of CRs. Six CR samples were studied. The expression of S6K1, pErk, Erk, Akt, pAkt, 4E-BP1, hamartin, tuberin, mTOR, bcl-2, Bax, and Ki-67 was examined using immunohistochemistry and Western blot methods. Increased expression of Bax, mTOR, pS6K, pErk, and 4E-BP1 was found in all CR samples. Hamartin and tuberin expression was decreased in tumors versus normal heart tissues. This is the first study showing mTOR pathway dysregulation and an increased expression of proapoptotic Bax protein in CRs associated with TSC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17990907     DOI: 10.2350/06-11-0191.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  7 in total

Review 1.  Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.

Authors:  Felipe Mussi von Ranke; Gláucia Zanetti; Jorge Luiz Pereira e Silva; Cesar Augusto Araujo Neto; Myrna C B Godoy; Carolina A Souza; Alexandre Dias Mançano; Arthur Soares Souza; Dante Luiz Escuissato; Bruno Hochhegger; Edson Marchiori
Journal:  Lung       Date:  2015-06-24       Impact factor: 2.584

Review 2.  Molecular therapies for tuberous sclerosis and neurofibromatosis.

Authors:  David Neal Franz; Brian D Weiss
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

3.  mTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia.

Authors:  Hongju Chen; Tao Xiong; Yi Qu; Fengyan Zhao; Donna Ferriero; Dezhi Mu
Journal:  Neurosci Lett       Date:  2011-12-08       Impact factor: 3.046

4.  Rapid resolution of cardiac rhabdomyomas following everolimus therapy.

Authors:  Swati Choudhry; Hoang Hiep Nguyen; Shafkat Anwar
Journal:  BMJ Case Rep       Date:  2015-12-09

5.  Sirolimus-Induced Regression of Tuberous Sclerosis-Associated Cardiac Rhabdomyoma Causing Left Ventricular Outflow Tract Obstruction.

Authors:  Colin Winkie; Jacob Gelman; Pieter Verhoeven; Nita Ray Chaudhuri
Journal:  CASE (Phila)       Date:  2022-05-20

Review 6.  Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review.

Authors:  Monika Sugalska; Anna Tomik; Sergiusz Jóźwiak; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-05-05       Impact factor: 3.390

7.  Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients.

Authors:  Mari Wataya-Kaneda; Mari Tanaka; Toshimitsu Hamasaki; Ichiro Katayama
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.